Compare EPRT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPRT | RYTM |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.8B |
| IPO Year | 2018 | 2017 |
| Metric | EPRT | RYTM |
|---|---|---|
| Price | $25.61 | $90.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 18 |
| Target Price | $36.20 | ★ $138.59 |
| AVG Volume (30 Days) | ★ 1.9M | 616.9K |
| Earning Date | 10-21-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | 11.30 | ★ 28.34 |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $561,219,000.00 | N/A |
| Revenue This Year | $19.04 | $65.10 |
| Revenue Next Year | $15.71 | $78.21 |
| P/E Ratio | $41.35 | ★ N/A |
| Revenue Growth | ★ 24.82 | N/A |
| 52 Week Low | $25.37 | $74.50 |
| 52 Week High | $34.73 | $122.20 |
| Indicator | EPRT | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 17.54 | 25.33 |
| Support Level | N/A | $82.43 |
| Resistance Level | $31.49 | $92.51 |
| Average True Range (ATR) | 0.52 | 3.53 |
| MACD | -0.05 | -0.53 |
| Stochastic Oscillator | 8.69 | 7.14 |
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.